– Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan), to its investigational CDH17-targeting ADC HS-20110.
– Hansoh Pharma will receive an upfront payment of US$80 million and is eligible to receive milestone payments, as well as royalties on potential future product sales.
On October 17, 2025, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) announced that it has entered into a license agreement with Roche for HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor (TOPOi) payload. Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to progress the clinical development and commercialization of HS-20110.
Under the agreement, Hansoh Pharma will receive an upfront payment of US$80 million and is eligible to receive development, regulatory approval, and commercialization milestone payments, as well as royalties on potential future product sales.
Eliza Sun, Executive Director of the Board, Hansoh Pharma, said: “HS-20110 is a promising CDH17-targeting ADC with early clinical activity noted in solid tumors including colorectal cancer (CRC). Partnering with Roche enables HS-20110 to move faster toward potential approval and patient access, furthering Hansoh’s commitment to bringing potentially transformative treatments to people with cancer around the world.”
About HS-20110
HS-20110 is a novel potentially first-in-class antibody-drug conjugate composed of a humanized anti-CDH17 monoclonal antibody covalently conjugated to topoisomerase inhibitor (TOPOi) payload. HS-20110 exhibits broad potential across solid tumors, and is currently being developed for the treatment of colorectal cancer and other solid tumors with a global Phase I trial underway in China and the United States.
